ICMJE DISCLOSURE FORM

Date:	1/31/2022
Your Name:	SFK Lubeek
Manuscript Title:	Overbehandeling van patiënten met basaalcelcarcinoom: actief observeren moet vaker worden overwogen
Manuscript Number (if known):	D6630

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 months	Click the tab key to add additional rows.		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Sun Pharmaceutical Industries Europe b.v.	Advisory board meeting (paid to the independent research fund of the department of dermatology of the Radboud university medical centre Nijmegen, the Netherlands)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Sanofi Genzyme	Speakers fee symposium (paid to the independent research fund of the department of dermatology of the Radboud university medical centre Nijmegen, the Netherlands)
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13 Other financial or non-financial None					
	interests	Sanofi Genzyme	Board member fee "niet-melanoom skin cancer" platform (paid to the independent research fund of the department of dermatology of the Radboud university medical centre Nijmegen, the Netherlands)		
Please place an "X" next to the following statement to indicate your agreement:					
\boxtimes	☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.				